Skip to main content
Citi Pharma Ltd. logo

Citi Pharma Ltd. — Investor Relations & Filings

Ticker · CPHL ISIN · PK0126201018 PSX Manufacturing
Open in API
Filings indexed 101 across all filing types
Latest filing 2026-05-21 Capital/Financing Update
Country PK Pakistan
Listing PSX CPHL

About Citi Pharma Ltd.

https://www.citipharma.com.pk/

Citi Pharma Ltd. is a prominent pharmaceutical company specializing in the manufacturing and sale of pharmaceuticals, medical chemicals, and botanical products. It is a leading producer of Active Pharmaceutical Ingredients (APIs), with key products including Paracetamol, Penicillin, and Amoxicillin. The company delivers high-quality pharmaceutical services to a global market while maintaining a significant presence in local API manufacturing. Citi Pharma is dedicated to expanding its generic pharmaceutical portfolio and is actively engaged in research and development, notably in developing locally manufactured insulin to reduce import reliance. The company is also strategically advancing into biotechnology and oncology, driven by innovation and strategic collaborations, such as those with the Gates Foundation, to integrate advanced biotech technologies.

Recent filings

Filing Released Lang Actions
Material Information
Capital/Financing Update Classification · 30% confidence The text is a corporate press release announcing a strategic financial partnership and advisory agreement focused on capital markets, IPOs, fundraising, and related financing activities. It is not a formal financial report, dividend notice, or regulatory filing. It best fits the Capital/Financing Update category.
2026-05-21 English
Material Information
M&A Activity Classification · 95% confidence The document is a formal announcement to the Pakistan Stock Exchange of the Board’s approval of a proposed acquisition of 100% shareholding in another pharmaceutical company. It details transaction structure, consideration, due diligence requirements, and strategic rationale. This clearly fits the M&A Activity category rather than a full annual report, earnings release or regulatory filing notice.
2026-05-06 English
Transmission of Quarterly Report for the Period Ended 31st March 2026
Interim / Quarterly Report Classification · 98% confidence The document is titled 'CONDENSED INTERIM FINANCIAL STATEMENTS (UN-AUDITED) FOR THE PERIOD ENDED MARCH 31, 2026' and contains detailed financial statements including statement of financial position, profit or loss, and directors' report for the interim period ending March 31, 2026. It references IAS 34 'Interim Financial Reporting' which is the standard for interim reports. The document is approximately 15,000 characters long, indicating it is a full report rather than a brief announcement. The content includes comprehensive financial data and management commentary for a period shorter than a full fiscal year (quarterly or nine months). Therefore, this document fits the definition of an Interim / Quarterly Report (IR). 9M 2026
2026-04-30 English
Financial Results for the Quarter Ended 31 March 2026
Regulatory Filings
2026-04-30 English
Material Information
Regulatory Filings Classification · 100% confidence The document text is extremely short (66 characters) and contains no substantive content, financial data, or any indication of report type. It only mentions 'CamScanner' and an omitted picture, which suggests it is not a financial or regulatory filing. Given the lack of content, the document cannot be classified as any specific report type and defaults to the fallback category 'Regulatory Filings' (RNS).
2026-03-03 English
Presentation - Corporate Briefing Session
Regulatory Filings
2026-02-27 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.